Here, we report the case of a patient with advanced lung adenocarcinoma with negative driver genes, who benefited from treatment with anti-programmed cell death-1 (anti-PD-1) therapy combined with a low dose of apatinib. From February 2020, the patient was treated with camrelizumab combined with pemetrexed disodium. The treatment regimen was adjusted to camrelizumab combined with a low dose of apatinib every 3 weeks because the patient could not tolerate the side effects of the previous chemotherapy, and camrelizumab led to reactive cutaneous capillary endothelial proliferation (RCCEP). After six cycles of camrelizumab plus a low dose of apatinib, the curative effect achieved was complete response (CR), with milder symptoms of RCCEP than before. Until the follow-up time of March 2021, the efficacy evaluation reached CR and the symptoms of RCCEP disappeared. This case report provides a theoretical basis for camrelizumab combined with a low dose of apatinib for the treatment ofcarcinoma patients with advanced lung adenocarcinoma with negative driver genes.

在这里，我们报告了一名驱动基因阴性的晚期肺腺癌患者的病例，该患者受益于抗程序性细胞死亡 1 (anti-PD-1) 疗法联合低剂量阿帕替尼的治疗。2020年2月起，患者接受卡瑞利珠单抗联合培美曲塞二钠治疗。治疗方案调整为卡瑞利珠单抗联合小剂量阿帕替尼每3周一次，因为患者不能耐受之前化疗的副作用，卡瑞利珠单抗导致反应性皮肤毛细血管内皮增生(RCEP)。经过六个周期的卡瑞利珠单抗加低剂量阿帕替尼后，取得的疗效为完全缓解（CR），RCCEP 症状比之前更轻。至随访时间2021年3月，疗效评价达CR，RCCEP症状消失。本病例报告为卡瑞利珠单抗联合小剂量阿帕替尼治疗驱动基因阴性的晚期肺腺癌患者提供了理论依据。